The SMYD3-ERK5 signaling module in pancreatic cancer
胰腺癌中的 SMYD3-ERK5 信号模块
基本信息
- 批准号:9128576
- 负责人:
- 金额:$ 14.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-09-01 至 2017-01-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAdenocarcinoma CellApoptosisAutomobile DrivingAwardBiochemicalCancer BiologyCancer EtiologyCancer cell lineCell SurvivalCellsCessation of lifeClinicalClinical TrialsDataDevelopmentDiseaseDrug TargetingDrug resistanceEventFamilyFeedbackGeneticGoalsGrowthHealthHumanIn VitroIncidenceInvestigationKRAS2 geneKnowledgeLeadLysineMAP2K1 geneMAPK3 geneMAPK7 geneMaintenanceMalignant NeoplasmsMalignant neoplasm of pancreasMentorsMethylationMethyltransferaseMitogen-Activated Protein KinasesModelingMolecularMusMutationNatureOncogenicPancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPharmacotherapyPhasePhosphotransferasesPlayPre-Clinical ModelProteinsRecurrenceRelapseResearchResistanceResistance developmentRoleSMYD3 geneScienceScientistSignal TransductionStimulusSystems BiologyTestingTherapeuticToxic effectTrainingValidationWorkbasecancer initiationcancer typecareercell motilitychemotherapyfield studygenetic approachimprovedin vivoinhibitor/antagonistinnovationinsightinterestkinase inhibitormembermortalitymouse modelnew therapeutic targetnext generationnovelpancreatic cancer cellspreventresearch studyresponseskillstherapeutic targettherapy resistanttranscription factortumortumor progressiontumor xenograft
项目摘要
DESCRIPTION (provided by applicant): My long-term career goal is to lead a productive academic research group, promoting science by conducting impactful cancer biology research and mentoring the next generation of dedicated scientists. I am particularly interested in the mechanisms of cancer development and resistance to therapy in Ras-driven tumors. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, and it is almost universally driven by activation of oncogenic Ras. Unfortunately, PDAC mortality rates have remained almost equal to incidence rates over the past few decades. My main objective is to identify novel therapeutic targets in PDAC cells to guide the development of new efficacious drugs and treatment approaches in PDAC patients. A major goal of this K99/R00 proposal is to elucidate a novel signaling module implicated in PDAC: in this module, the SMYD3 lysine methyltransferase activates the MAP3K2 kinase, which in turn activates the MEK5 kinase, leading to activation of the downstream ERK5 kinase. A second important goal is to uncover molecular mechanisms promoting resistance to drugs targeting the Ras pathway. First, I will focus on defining the role of ERK5 in the initiation and progression of PDAC. The MEK5-ERK5 pathway has been implicated in cell survival and cell motility but its role in PDAC has never been investigated. Aim
1 will test the hypothesis that activation of the SMYD3-ERK5 signaling module, which I have recently observed in PDAC, facilitates early cancer progression by promoting pancreatic cell plasticity, proliferation, and impairing apoptosis in response to oncogenic Ras. I will use genetic
and pharmacological approaches to test this hypothesis in mouse models of PDAC, patient derived tumor xenografts, and cancer cell lines. Clinical trials with inhibitors of kinases in the canonical Ras pathway have had disappointing results, in part because of the rapid emergence of resistant tumors. I have generated pre-clinical models to study tumors resistant to Ras pathway inhibitors and found amplification of SMYD3-ERK5 activity during tumor relapse. Aim 2 will utilize genetic and pharmacological approaches to characterize the functional role of the SMYD3- ERK5 signaling module in resistant tumors in vivo and in vitro. Finally, in Aim 3, I will perform an unbiased screen of transcriptional targets and interacting protein partners of ERK5 to elucidate its mechanisms of action in PDAC cells and identify novel key regulators of PDAC development and resistance to Ras pathway inhibitors. Candidate targets, including preliminarily identified YAP1 transcription factor, will be tested in a novel mouse model of human PDAC that I have developed for rapid investigation of putative regulators of disease development in vivo. A K99/R00 training award will allow me to carry out this transformative project, further developing my current skills in mouse genetics and cancer biology, while also allowing me to acquire knowledge in clinical aspects of pancreatic cancer and new expertise in biochemical signaling and systems biology.
描述(由申请人提供):我的长期职业目标是领导一个富有成效的学术研究小组,通过进行有影响力的癌症生物学研究和指导下一代敬业的科学家来促进科学发展。我对 Ras 驱动的肿瘤的癌症发展机制和治疗耐药性特别感兴趣。胰腺导管腺癌 (PDAC) 是最致命的癌症之一,几乎普遍由致癌 Ras 的激活引起。不幸的是,在过去的几十年里,PDAC 的死亡率几乎与发病率持平。我的主要目标是确定 PDAC 细胞中的新治疗靶点,以指导 PDAC 患者新有效药物和治疗方法的开发。 K99/R00 提案的一个主要目标是阐明 PDAC 中涉及的一种新型信号传导模块:在该模块中,SMYD3 赖氨酸甲基转移酶激活 MAP3K2 激酶,进而激活 MEK5 激酶,从而激活下游 ERK5 激酶。第二个重要目标是揭示促进针对 Ras 途径的药物耐药性的分子机制。首先,我将重点定义 ERK5 在 PDAC 的启动和进展中的作用。 MEK5-ERK5 通路与细胞存活和细胞运动有关,但其在 PDAC 中的作用从未被研究过。目的
我最近在 PDAC 中观察到,SMYD3-ERK5 信号传导模块的激活通过促进胰腺细胞可塑性、增殖和响应致癌 Ras 损害细胞凋亡来促进早期癌症进展,图 1 将检验这一假设。我会用基因
以及在 PDAC 小鼠模型、患者来源的肿瘤异种移植物和癌细胞系中检验这一假设的药理学方法。经典 Ras 通路激酶抑制剂的临床试验结果令人失望,部分原因是耐药肿瘤的迅速出现。我已经建立了临床前模型来研究对 Ras 通路抑制剂耐药的肿瘤,并发现肿瘤复发期间 SMYD3-ERK5 活性的放大。目标 2 将利用遗传和药理学方法来表征 SMYD3-ERK5 信号模块在体内和体外耐药肿瘤中的功能作用。最后,在目标 3 中,我将对 ERK5 的转录靶点和相互作用蛋白伴侣进行无偏筛选,以阐明其在 PDAC 细胞中的作用机制,并确定 PDAC 发育和 Ras 途径抑制剂抗性的新型关键调节因子。候选靶点,包括初步鉴定的 YAP1 转录因子,将在我开发的新型人类 PDAC 小鼠模型中进行测试,该模型是为了快速研究体内疾病发展的假定调节因子。 K99/R00 培训奖将使我能够开展这一变革性项目,进一步发展我目前在小鼠遗传学和癌症生物学方面的技能,同时也使我能够获得胰腺癌临床方面的知识以及生化信号和系统生物学方面的新专业知识。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Pancreatic cancer takes its Toll.
胰腺癌造成了损失。
- DOI:10.1084/jem.21212insight1
- 发表时间:2015-11-16
- 期刊:
- 影响因子:0
- 作者:Mazur PK;Sage J
- 通讯作者:Sage J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pawel K. Mazur其他文献
An integrative cross-tumors approach identifies FOSL1 as an oncogene dependency in KRAS-driven lung cancer
- DOI:
10.1016/j.jtho.2015.12.084 - 发表时间:
2016-02-01 - 期刊:
- 影响因子:
- 作者:
Adrian Vallejo;Naiara Perurena;Elizabeth Guruceaga;Pawel K. Mazur;Susana Martinez-Canarias;Carolina Zandueta;Dana Gwinn;Leanne C. Sayles;Chen-Hua Chuang;Jesper B. Andersen;Aline Bozec;Alejandro Sweet-Cordero;Julien Sage;Fernando Lecanda;Silvestre Vicent - 通讯作者:
Silvestre Vicent
ASIC – LIVER , PANCREAS , AND BILIARY RACT otch Signaling Is Required for Exocrine Regeneration After cute Pancreatitis
ASIC – 肝脏、胰腺和胆管 otch 信号是可爱胰腺炎后外分泌再生所必需的
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
Ens T. Siveke;C. L. –. Martellato;Marcel Lee;Pawel K. Mazur;H. Nakhai;R. Radtke;R. Schmid - 通讯作者:
R. Schmid
Pawel K. Mazur的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pawel K. Mazur', 18)}}的其他基金
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
胃癌进展和治疗耐药中的肿瘤细胞谱系多样性和组成
- 批准号:
10662203 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance
胃癌进展和治疗耐药中的肿瘤细胞谱系多样性和组成
- 批准号:
10342536 - 财政年份:2022
- 资助金额:
$ 14.72万 - 项目类别:
Role of SETD5 in Chromatin Regulation and Tumorigenesis
SETD5 在染色质调节和肿瘤发生中的作用
- 批准号:
10586057 - 财政年份:2019
- 资助金额:
$ 14.72万 - 项目类别:
Role of SETD5 in Chromatin Regulation and Tumorigenesis
SETD5 在染色质调节和肿瘤发生中的作用
- 批准号:
10429907 - 财政年份:2019
- 资助金额:
$ 14.72万 - 项目类别:
The SMYD3-ERK5 signaling module in pancreatic cancer
胰腺癌中的 SMYD3-ERK5 信号模块
- 批准号:
8950606 - 财政年份:2015
- 资助金额:
$ 14.72万 - 项目类别:
相似海外基金
Assessing The Impact of Heparanase and NDST2 Expression on Non-Small Cell Lung Adenocarcinoma Cell Motility
评估乙酰肝素酶和 NDST2 表达对非小细胞肺腺癌细胞运动的影响
- 批准号:
449570 - 财政年份:2020
- 资助金额:
$ 14.72万 - 项目类别:
Studentship Programs
Analysis of cancer metastasis and invasion mechanism using a new lung adenocarcinoma cell line.
使用新的肺腺癌细胞系分析癌症转移和侵袭机制。
- 批准号:
16K10689 - 财政年份:2016
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Acquisition strategy of tumor-specific markers using established micropapillary pattern pulmonary adenocarcinoma cell line
使用已建立的微乳头模式肺腺癌细胞系获取肿瘤特异性标志物的策略
- 批准号:
26460441 - 财政年份:2014
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The antibetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
抗生素药物二甲双胍在体外和体内抑制食管腺癌细胞增殖。
- 批准号:
25860540 - 财政年份:2013
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The cell permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferations and can be used as the molecular targeting dru
细胞通透肽抑制胰腺导管腺癌细胞增殖,可作为分子靶向药物
- 批准号:
25461969 - 财政年份:2013
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Basic Research for elucidation of chemo-resistance in mucinous adenocarcinoma cell.
阐明粘液腺癌细胞化疗耐药性的基础研究。
- 批准号:
22791532 - 财政年份:2010
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
TAS::75 0849::TAS IN THIS PHASE I SBIR THE BREAST CANCER ADENOCARCINOMA CELL LI
TAS::75 0849::TAS 在这一阶段 I SBIR 乳腺癌腺癌细胞 LI
- 批准号:
8164743 - 财政年份:2010
- 资助金额:
$ 14.72万 - 项目类别:
Role of Endothelin-1 in osteoblastic bone metastasis produced by a human lung adenocarcinoma cell line
Endothelin-1 在人肺腺癌细胞系产生的成骨细胞骨转移中的作用
- 批准号:
19790127 - 财政年份:2007
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
CONNEXIN 43 EXPRESSION IN ADENOCARCINOMA CELL LINE
连接蛋白 43 在腺癌细胞系中的表达
- 批准号:
6972483 - 财政年份:2004
- 资助金额:
$ 14.72万 - 项目类别:
The mechanisms of highly metastetic capasity in highly metastatic subpopulations of lung adenocarcinoma cell line and these clinical applications
肺腺癌细胞系高转移亚群的高转移能力机制及临床应用
- 批准号:
15590831 - 财政年份:2003
- 资助金额:
$ 14.72万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




